Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report)’s share price rose 8.9% during trading on Thursday . The stock traded as high as $0.40 and last traded at $0.3877. 6,543 shares were traded during mid-day trading, an increase of 15% from the average session volume of 5,685 shares. The stock had previously closed at $0.3560.
Avenue Therapeutics Stock Performance
The stock has a market capitalization of $1.28 million, a price-to-earnings ratio of 0.02 and a beta of -0.17. The business has a 50 day simple moving average of $0.31 and a 200-day simple moving average of $0.34.
About Avenue Therapeutics
Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.
The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.
Read More
- Five stocks we like better than Avenue Therapeutics
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
- MarketBeat Week in Review – 07/27- 07/31
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
